APA

Banerji U., Camidge D. R., Verheul H. M. W., Agarwal R., Sarker D., Kaye S. B., Desar I. M. E., Timmer-Bonte J. N. H., Eckhardt S. G., Lewis K. D., Brown K. H., Cantarini M. V., Morris C., George S. M. A., Smith P. D. & van Herpen C. M. L. (20100520). The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Banerji Udai, Camidge D Ross, Verheul Henk M W, Agarwal Roshan, Sarker Debashis, Kaye Stan B, Desar Ingrid M E, Timmer-Bonte Johanna N H, Eckhardt S Gail, Lewis Karl D, Brown Kathryn H, Cantarini Mireille V, Morris Clive, George Sarah M A, Smith Paul D and van Herpen Carla M L. 20100520. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Banerji U., Camidge D. R., Verheul H. M. W., Agarwal R., Sarker D., Kaye S. B., Desar I. M. E., Timmer-Bonte J. N. H., Eckhardt S. G., Lewis K. D., Brown K. H., Cantarini M. V., Morris C., George S. M. A., Smith P. D. and van Herpen C. M. L. (20100520). The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Banerji Udai, Camidge D Ross, Verheul Henk M W, Agarwal Roshan, Sarker Debashis, Kaye Stan B, Desar Ingrid M E, Timmer-Bonte Johanna N H, Eckhardt S Gail, Lewis Karl D, Brown Kathryn H, Cantarini Mireille V, Morris Clive, George Sarah M A, Smith Paul D and van Herpen Carla M L. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20100520.